OR4K3 Antibody

What is OR4K3 and why is it significant in scientific research?

OR4K3 (Olfactory receptor 4K3) is a member of the olfactory receptor family involved in detecting specific odor molecules and triggering physiological responses. It belongs to the G-protein coupled receptor 1 family and functions as an odorant receptor. The significance of OR4K3 lies in its role within the olfactory system, where it helps detect specific odor molecules and triggers signal transduction pathways that allow the brain to process and interpret odor signals . Studying OR4K3 contributes to our understanding of sensory perception, particularly how humans detect and process olfactory stimuli, which has implications for neuroscience and signal transduction research .

What are the key specifications of commercially available OR4K3 antibodies?

OR4K3 antibodies are primarily polyclonal antibodies produced in rabbits, targeting specific regions of the human OR4K3 protein. Based on available data, these antibodies have the following specifications:

These antibodies are affinity-purified from rabbit antiserum using epitope-specific immunogen to ensure specificity and reduce background .

What are the optimal protocols for using OR4K3 antibody in Western blotting?

For optimal Western blot results with OR4K3 antibody, follow these methodological guidelines:

• Sample Preparation:

  • For cell lysates (e.g., from HeLa or Jurkat cells), use RIPA buffer supplemented with protease inhibitors.

  • Heat samples at 95°C for 5 minutes in sample buffer containing SDS and a reducing agent.

• Gel Electrophoresis and Transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation.

  • Transfer proteins to PVDF membrane (preferred over nitrocellulose for hydrophobic membrane proteins).

• Blocking and Antibody Incubation:

  • Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

  • Dilute primary OR4K3 antibody 1:500-1:2000 in blocking buffer.

  • Incubate membrane with primary antibody overnight at 4°C with gentle agitation.

  • Wash 3-5 times with TBST, 5 minutes each.

  • Incubate with HRP-conjugated secondary antibody (anti-rabbit IgG) at 1:5000-1:10000 for 1 hour at room temperature.

• Detection:

  • Wash 3-5 times with TBST, 5 minutes each.

  • Apply ECL substrate and image using a digital imaging system.

When optimizing, remember that OR4K3 as a membrane protein may require special consideration for extraction and detection. The expected molecular weight is approximately 72 kDa, though the calculated weight is 35.4 kDa . For validation, peptide blocking experiments can confirm antibody specificity, as demonstrated in the Boster Bio validation images .

How can OR4K3 antibody be effectively used in immunofluorescence studies?

For effective immunofluorescence (IF) studies with OR4K3 antibody, follow this optimized protocol:

• Cell Preparation:

  • Culture cells (A549 cells have been successfully used) on coverslips in appropriate medium.

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature.

  • Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes.

• Blocking and Antibody Incubation:

  • Block with 5% normal serum (corresponding to secondary antibody species) for 1 hour.

  • Dilute OR4K3 antibody 1:200-1:1000 in blocking buffer.

  • Incubate overnight at 4°C in a humidified chamber.

  • Wash 3 times with PBS, 5 minutes each.

  • Incubate with fluorophore-conjugated secondary antibody (1:500) for 1 hour at room temperature in the dark.

  • Wash 3 times with PBS, 5 minutes each.

• Counterstaining and Mounting:

  • Counterstain nuclei with DAPI (1:1000) for 5 minutes.

  • Mount with anti-fade mounting medium.

• Controls and Validation:

  • Include a negative control by omitting primary antibody.

  • For specificity validation, perform peptide competition assay by pre-incubating antibody with blocking peptide.

Boster Bio has successfully validated their OR4K3 antibody in A549 cells, demonstrating specific staining that could be blocked with synthetic peptide . For membrane proteins like OR4K3, careful optimization of permeabilization conditions is critical to balance sufficient access to the epitope while preserving membrane structure.

What validation methods should be employed to confirm OR4K3 antibody specificity?

To ensure robust and reproducible results, multiple validation methods should be employed to confirm OR4K3 antibody specificity:

• Peptide Competition/Blocking Assay:

  • Pre-incubate antibody with synthetic peptide (the immunogen).

  • Run parallel experiments with blocked and unblocked antibody.

  • Specific signals should disappear or significantly decrease in the blocked sample.

  • This has been successfully demonstrated for OR4K3 antibodies from multiple vendors .

• Western Blot Size Verification:

  • Verify that the detected band appears at the expected molecular weight (approximately 72 kDa for OR4K3).

  • Check for clean bands without excessive non-specific binding.

• Positive and Negative Controls:

  • Use cell lines known to express OR4K3 (e.g., HeLa, Jurkat, A549) as positive controls.

  • Use cell lines with confirmed low or no expression as negative controls.

  • If possible, use OR4K3 knockout or knockdown samples.

• Cross-Technique Validation:

  • Confirm findings across multiple techniques (WB, IF, ELISA).

  • Consistent results across different methods strengthen confidence in antibody specificity.

• Multiple Antibody Comparison:

  • If available, compare results from different antibodies targeting different epitopes of OR4K3.

  • Consistent results with multiple antibodies increase confidence in specificity.

These validation approaches are essential for avoiding artifacts and ensuring that experimental observations truly reflect OR4K3 biology rather than non-specific interactions .

How do expression patterns of OR4K3 vary across different tissues and cell types?

OR4K3, while primarily associated with the olfactory system, shows interesting expression patterns across various tissues and cell types that can be detected using the appropriate antibody:

When investigating OR4K3 expression patterns, it's advisable to use multiple detection methods (protein and mRNA) for confirmation, as expression levels may be low in non-olfactory tissues. Additionally, subcellular localization studies using fractionation techniques can provide insights into the protein's function in different cellular compartments.

What are the current hypotheses about OR4K3's role in signal transduction pathways?

Current research on OR4K3 and related olfactory receptors suggests several hypotheses about its role in signal transduction:

• Classical Olfactory Signaling:

  • OR4K3, like other olfactory receptors, is believed to couple with G proteins upon odorant binding.

  • This activation triggers adenylyl cyclase, increasing cAMP levels and opening cyclic nucleotide-gated channels.

  • The resulting calcium influx depolarizes the neuron, initiating action potentials that are transmitted to the brain.

• Non-Canonical Signaling Pathways:

  • Beyond classical olfactory signaling, OR4K3 may participate in alternative signal transduction pathways in non-olfactory tissues.

  • Research categorization of OR4K3 antibodies under "Signal transduction" research areas suggests its involvement in broader signaling mechanisms .

• Potential Interaction Networks:

  • As a G-protein coupled receptor, OR4K3 likely interacts with various downstream effector proteins.

  • These interactions may vary between different tissue types, potentially explaining its presence in diverse cell types.

• Pathophysiological Implications:

  • Expression in cancer cell lines (HeLa, A549) raises questions about potential roles in cancer biology.

  • The detection of OR4K3 in Jurkat cells (T lymphocyte line) suggests possible functions in immune responses.

To investigate these hypotheses, researchers might employ the OR4K3 antibody in co-immunoprecipitation experiments to identify interaction partners, or in phosphorylation-specific assays to elucidate downstream signaling events following receptor activation. Combining antibody-based detection with functional assays (calcium imaging, cAMP measurements) would provide more comprehensive insights into OR4K3's signaling mechanisms.

What considerations should be made when studying OR4K3 in comparative animal models?

When using OR4K3 antibodies in comparative animal studies, researchers should consider several important factors:

• Sequence Homology and Cross-Reactivity:

  • While some OR4K3 antibodies are reported to cross-react with mouse and rat orthologs , the degree of sequence conservation should be verified.

  • The immunogen sequence (typically from the C-terminal region, AA 266-315 in human OR4K3) should be aligned across species to predict cross-reactivity.

  • Explicit validation in each species is necessary, as vendors' claims of cross-reactivity may not have been extensively tested.

• Evolutionary Divergence of Olfactory Receptors:

  • Olfactory receptors evolve rapidly and show significant species-specific adaptations.

  • Paralogs within a species may show similar epitopes, potentially leading to cross-reactivity with related olfactory receptors.

  • Negative controls using tissues from receptor knockout animals are ideal but may not be available for OR4K3.

• Experimental Design Considerations:

  • Include species-specific positive controls (tissues known to express OR4K3).

  • Validate antibody specificity separately for each species through peptide blocking experiments.

  • Consider complementary approaches (in situ hybridization, RT-PCR) to corroborate protein expression data.

• Differential Expression Patterns:

  • Expression patterns of OR4K3 may differ significantly between species due to ecological adaptations.

  • Quantitative comparisons should account for these natural variations rather than assuming identical expression profiles.

When designing comparative studies, researchers should consider both the molecular evolution of OR4K3 and the technical limitations of cross-species antibody reactivity. Preliminary validation experiments in each species of interest are essential before proceeding with larger comparative studies.

What are the common challenges in Western blot detection of OR4K3 and how can they be addressed?

Detection of OR4K3 by Western blot presents several challenges common to membrane-associated G-protein coupled receptors:

• Protein Extraction Challenges:

  • Problem: Inefficient extraction due to hydrophobic transmembrane domains.

  • Solution: Use stronger lysis buffers containing 1-2% SDS or specialized membrane protein extraction kits. Avoid excessive heating which can cause aggregation of membrane proteins.

• Multiple or Smeared Bands:

  • Problem: OR4K3 may appear as multiple bands or smears due to post-translational modifications, particularly glycosylation.

  • Solution: For clearer bands, consider treating samples with glycosidases. To confirm specificity, use peptide competition assays as demonstrated in validation studies .

• Discrepancy in Molecular Weight:

  • Problem: The observed molecular weight (72 kDa) differs significantly from the calculated weight (35.4 kDa) .

  • Solution: This is normal for membrane proteins; always look for bands at the experimentally validated 72 kDa size rather than the theoretical weight.

• Weak Signal Intensity:

  • Problem: Low expression levels in non-olfactory tissues.

  • Solution: Increase protein loading (up to 50-100 μg), use more concentrated primary antibody (1:500 rather than 1:2000), extend primary antibody incubation to overnight at 4°C, and use high-sensitivity ECL substrates.

• Background Issues:

  • Problem: High background, particularly with polyclonal antibodies.

  • Solution: More stringent blocking (5% BSA instead of milk for phospho-specific detection), increase washing duration and number of washes, and optimize antibody dilutions through titration experiments.

When troubleshooting, systematic variation of one parameter at a time is recommended, with appropriate controls in each experiment to validate improvements.

How can researchers optimize immunofluorescence protocols specifically for OR4K3 detection?

Optimizing immunofluorescence protocols for OR4K3 requires addressing several membrane protein-specific challenges:

• Fixation and Permeabilization Optimization:

  • Challenge: Overfixation can mask epitopes, while excessive permeabilization can disrupt membrane structure.

  • Solution: Compare multiple fixation methods (4% PFA, methanol, or combination fixation) and permeabilization agents (0.1-0.5% Triton X-100, 0.1-0.5% Saponin, or 0.01-0.05% SDS) to determine optimal conditions.

  • For OR4K3, mild permeabilization with 0.2% Triton X-100 for 5-10 minutes has shown good results in A549 cells .

• Signal Amplification Strategies:

  • Challenge: Low endogenous expression can result in weak signals.

  • Solution: Consider tyramide signal amplification (TSA) methods, which can enhance sensitivity 10-100 fold compared to conventional detection.

  • Alternatively, use more sensitive detection systems like quantum dots or highly cross-adsorbed secondary antibodies.

• Autofluorescence Reduction:

  • Challenge: Cells and tissues often have intrinsic autofluorescence that can mask specific signals.

  • Solution: Include Sudan Black B (0.1-0.3%) treatment after secondary antibody incubation to quench autofluorescence, or use spectral imaging systems that can distinguish between autofluorescence and specific signals.

• Antibody Concentration and Incubation Optimization:

  • Challenge: Finding the optimal balance between signal strength and background.

  • Solution: Perform antibody titration experiments (testing dilutions from 1:100 to 1:1000) and vary incubation times (1 hour at room temperature vs. overnight at 4°C).

  • Results from Boster Bio suggest starting with 1:200-1:1000 dilutions for IF applications with OR4K3 antibody .

• Confocal Imaging Optimization:

  • Challenge: Capturing membrane-localized signals with optimal resolution.

  • Solution: Adjust pinhole settings for optimal optical sectioning, use appropriate Z-stacking protocols, and consider super-resolution techniques for detailed subcellular localization studies.

Including appropriate controls (both positive controls using cells known to express OR4K3 and negative controls through peptide competition) is essential for validating the specificity of immunofluorescence signals, as demonstrated in the validation images from Boster Bio .

What strategies can be employed to improve antibody specificity when studying OR4K3 in complex tissue samples?

When studying OR4K3 in complex tissue samples such as olfactory epithelium or brain sections, improving antibody specificity requires multifaceted approaches:

• Antigen Retrieval Optimization:

  • Strategy: Compare different antigen retrieval methods (heat-induced with citrate buffer pH 6.0, Tris-EDTA pH 9.0, or enzymatic retrieval with proteinase K).

  • Rationale: Optimal epitope exposure is particularly important in fixed tissues where cross-linking can mask antigens.

• Dual Immunolabeling Approaches:

  • Strategy: Co-stain with antibodies against known olfactory neuron markers (e.g., OMP, adenylyl cyclase III) to confirm cell-type specific expression.

  • Rationale: Colocalization with established markers provides additional confidence in the specificity of OR4K3 labeling.

• Absorption Controls Beyond Standard Peptide Blocking:

  • Strategy: Perform pre-absorption not only with the immunizing peptide but also with peptides from closely related olfactory receptors.

  • Rationale: This helps rule out cross-reactivity with similar epitopes in the large olfactory receptor family.

• Complementary Detection Methods:

  • Strategy: Validate antibody labeling with in situ hybridization for OR4K3 mRNA or with reporter systems in model organisms.

  • Rationale: Concordance between protein and mRNA detection significantly strengthens confidence in antibody specificity.

• Tissue-Specific Protocol Modifications:

  • Strategy: Increase blocking stringency (5-10% serum with 0.1-0.3% Triton X-100 and 1-3% BSA) and extend blocking time (2-3 hours) for tissues with high background.

  • Rationale: Complex tissues often require more stringent blocking to reduce non-specific binding.

• Fluorophore Selection for Autofluorescent Tissues:

  • Strategy: Choose fluorophores with emission spectra distinct from tissue autofluorescence (far-red dyes often work well).

  • Rationale: This minimizes interference from endogenous fluorescent compounds in tissues.

• Multi-step Amplification Systems:

  • Strategy: Use biotin-streptavidin amplification or polymer-based detection systems rather than direct secondary antibody detection.

  • Rationale: These systems can improve sensitivity without increasing background when properly optimized.

These strategies should be systematically tested and combined as needed, with careful documentation of protocol variations to identify optimal conditions for specific tissue types.

How might OR4K3 antibodies contribute to understanding the non-canonical functions of olfactory receptors?

OR4K3 antibodies represent powerful tools for exploring emerging research on non-canonical functions of olfactory receptors beyond the nasal epithelium:

• Characterization of Ectopic Expression:

  • OR4K3 antibodies can help map the complete expression profile of this receptor across diverse tissue types and disease states.

  • The detection of OR4K3 in cell lines like HeLa, Jurkat, and A549 suggests potential roles in tissues not primarily associated with olfaction.

  • Systematic immunohistochemical studies across tissue arrays could reveal previously unknown expression patterns.

• Investigation of Novel Signaling Pathways:

  • OR4K3 antibodies can be used in co-immunoprecipitation experiments to identify novel interaction partners.

  • Phospho-specific antibodies could be developed to track activation-dependent signaling events.

  • Combining OR4K3 antibody-based detection with functional calcium imaging or cAMP assays could elucidate tissue-specific signaling mechanisms.

• Role in Pathological Conditions:

  • The presence of OR4K3 in cancer cell lines warrants investigation of its potential roles in tumor biology.

  • OR4K3 antibodies could be used to examine expression changes in various disease models, potentially revealing new pathophysiological mechanisms.

  • Correlating expression levels with clinical outcomes could identify OR4K3 as a potential biomarker.

• Receptor Trafficking and Regulation:

  • Antibodies against OR4K3 can help track receptor internalization, recycling, and degradation through subcellular fractionation and immunofluorescence studies.

  • Time-course experiments following stimulation could reveal dynamic regulation mechanisms.

• Therapeutic Target Potential:

  • If non-canonical functions of OR4K3 are validated in disease models, antibody-based studies could help evaluate its potential as a therapeutic target.

  • Monoclonal antibody development targeting specific epitopes could lead to function-blocking antibodies for experimental therapeutics.

These research directions represent exciting frontiers in understanding the multifaceted roles of olfactory receptors beyond their classical sensory functions .

What technical advances might improve OR4K3 antibody development and application in the future?

Several emerging technologies and approaches could significantly enhance OR4K3 antibody development and applications:

• Single B Cell Antibody Sequencing:

  • This technology allows isolation of B cells producing antibodies against specific epitopes, followed by sequencing and recombinant production.

  • For OR4K3, this could enable development of highly specific monoclonal antibodies targeting different epitopes, allowing more comprehensive protein characterization.

• Structural Biology-Guided Epitope Selection:

  • As more structural information becomes available for olfactory receptors, epitope selection could be guided by 3D structural data.

  • This approach could generate antibodies targeting functionally important domains of OR4K3, potentially yielding function-modulating antibodies.

• Recombinant Antibody Fragments:

  • Smaller antibody formats (Fab, scFv, nanobodies) derived from OR4K3-specific antibodies could offer advantages for certain applications:

    • Better tissue penetration for in vivo imaging

    • Reduced non-specific binding

    • Compatibility with super-resolution microscopy techniques

• Multiplexed Antibody-Based Assays:

  • Development of multiplexed detection systems would allow simultaneous analysis of OR4K3 along with interaction partners.

  • Techniques like Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) could correlate OR4K3 protein expression with transcriptional profiles at single-cell resolution.

• Advanced Conjugation Chemistries:

  • Site-specific conjugation methods could improve current OR4K3 antibodies by attaching fluorophores or other functional groups at defined positions.

  • This would ensure consistent performance across batches and potentially improve signal-to-noise ratios.

• Antibody Engineering for Difficult Epitopes:

  • For challenging epitopes in OR4K3, directed evolution approaches could yield antibodies with improved affinity and specificity.

  • Computational design methods could optimize antibody-antigen interactions.

• Quantitative Super-Resolution Imaging:

  • Next-generation OR4K3 antibodies optimized for super-resolution microscopy could reveal nanoscale organization of this receptor in specialized membrane domains.

  • This could provide unprecedented insights into its functional organization and interactions.

These technical advances would collectively enhance our ability to study OR4K3 with greater precision, potentially revealing new aspects of its biology in both canonical and non-canonical contexts.